Literature DB >> 9284849

Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans.

D W Boulton1, J P Fawcett.   

Abstract

Albuterol (INN, salbutamol) is a beta 2-adrenergic receptor agonist widely used in the treatment of asthma. It is administered clinically as a racemic mixture, but only one enantiomer is active (eutomer) while the other (distomer) has been implicated in causing toxicity. This study used a chiral assay to compare the pharmacokinetics and pharmacodynamics of racemic albuterol with its two enantiomers in a three-way crossover of single oral doses in 12 healthy males. The bioavailability of the eutomer was less than that of the distomer after administration of pure enantiomers and racemate. Apart from causing a small increase in plasma potassium, the distomer had no effect on any pharmacodynamic parameter. The eutomer administered alone was significantly more potent than an equivalent dose given as racemate with regard to its effects on heart rate, QTc interval, plasma potassium levels, and plasma glucose levels. Despite this higher potency, the area under the plasma concentration versus time curve for eutomer after administration of pure eutomer was significantly lower than after administration of the racemate. This difference is probably the result of the more efficient metabolism of the eutomer in the absence of the distomer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9284849     DOI: 10.1016/S0009-9236(97)90061-8

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

1.  Enantiomeric disposition of inhaled, intravenous and oral racemic-salbutamol in man--no evidence of enantioselective lung metabolism.

Authors:  J K Ward; J Dow; N Dallow; P Eynott; S Milleri; G P Ventresca
Journal:  Br J Clin Pharmacol       Date:  2000-01       Impact factor: 4.335

2.  Beta2-Agonist Doping Control and Optical Isomer Challenges.

Authors:  Glenn A Jacobson; J Paul Fawcett
Journal:  Sports Med       Date:  2016-12       Impact factor: 11.136

Review 3.  The pharmacokinetics of levosalbutamol: what are the clinical implications?

Authors:  D W Boulton; J P Fawcett
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

4.  Comparative pharmacokinetics and bile transformation of R-enantiomer and racemic bambuterol after single-dose intravenous, oral administration in rats and beagle dogs.

Authors:  Su Guan; Chun-Yun Hu; Meng-Ying He; Ying-Ying Yang; Yu-Xin Tang; Jie-di Chen; Li-Jie Huang; Wen Tan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-10-04       Impact factor: 2.441

5.  A population analysis of nebulized (R)-albuterol in dogs using a novel mixed gut-lung absorption PK-PD model.

Authors:  B Auclair; I W Wainer; K Fried; P Koch; T P Jerussi; M P Ducharme
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

6.  Stereoselective glucuronidation of formoterol by human liver microsomes.

Authors:  M Zhang; J P Fawcett; J M Kennedy; J P Shaw
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

Review 7.  Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol).

Authors:  Karim Makhlouf; Howard L Weiner; Samia J Khoury
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

8.  Albuterol enantiomer levels, lung function and QTc interval in patients with acute severe asthma and COPD in the emergency department.

Authors:  Kwang Choon Yee; Glenn A Jacobson; Richard Wood-Baker; E Haydn Walters
Journal:  Int J Emerg Med       Date:  2011-06-15

Review 9.  Single-isomer levalbuterol: a review of the acute data.

Authors:  Richard Nowak
Journal:  Curr Allergy Asthma Rep       Date:  2003-03       Impact factor: 4.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.